Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, curre...
Industry: Biotechnology
Sector: Healthcare
Phone: 32 1 534 29 00
Fax: 32 1 534 29 01
Address:
Generaal De Wittelaan L11 A3, Mechelen, Belgium
